Few domestic studies have integrated plasma Aβ, tau, and NfL simultaneously to evaluate their comprehensive diagnostic efficacy for AD and assess their consistency with classic CSF core biomarkers. The gene discussed is MAPT; the disease is Alzheimer disease.